Large increase in bloodstream infections with carbapenem-resistant Acinetobacter species during the first 2 years of the COVID-19 pandemic, EU/EEA, 2020 and 2021

  21 November 2022

Bloodstream infections (BSIs) with  species commonly have poor outcomes, especially in intensive care unit (ICU) patients.  spp. is intrinsically resistant to many antimicrobials, and additional acquired resistance further complicates the treatment of serious infections in already vulnerable patient groups. Recent data from the European Antimicrobial Resistance Surveillance Network (EARS-Net) show a large and statistically significant increase in reports of  spp. BSIs in the European Union (EU) and European Economic Area (EEA) during the period from 2017 to 2021. Most of this increase occurred in 2020 and 2021, the first years of the coronavirus disease (COVID-19) pandemic. Here we further explore this trend in a subset of data from laboratories that continuously reported data during that period.

Further reading: Eurosurveillance
Author(s): Pete Kinross et al
Effective Surveillance  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Ambassador Network

Join the AMR Insights Ambassador Network today!

Connect to over 550 AMR professionals and students in 60 countries!

More information
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!
Popup Plugin